



FOR IMMEDIATE RELEASE

Dover, Delaware, August 8, 2023

Immgenuity Inc., a leading biotechnology company, is proud to announce the appointment of former US Senator and former Governor George Allen to its Board of Directors.

Senator George Allen has had a distinguished career in local, state and federal governments. He served in the Virginia house of delegates from 1983 to 1991. In 1993, he was elected Governor of Virginia until 1998. As governor, he was the architect of a bipartisan welfare reform bill. He was also the prime mover behind "Truth in Sentencing Act" which passed both houses with overwhelming majorities. He was also a visionary in a SOLS program (Standards of Learning), supported enthusiastically by the American Federation of Teachers. The SOLS program was visionary in its emphasis on core subjects - way before anyone thought of STEM. From 1998 to 2000, Senator Allen became a partner in the law firm McGuire Woods LLP. He also served on the boards of Commonwealth Biotechnologies, Xybernaut and Com-Net Ericsson.

In 2000, he was elected to the US Senate. In the senate, he served on the Foreign Relations, Energy and Natural Resources, and Commerce, Science and Transportation Committees. His landmark accomplishment was the 21st Century Nanotechnology Research and Development Act.

For Immgenuity, Sen. Allen will be able to use his distinguished legal, administration and legislative skills to help the company have excellent corporate governance and help the company fulfill its strategic vision.

"We are thrilled to have Senator Allen join our Board of Directors," said Dr. Sateesh Apte, Immgenuity's CEO. "His depth of leadership, governance experience and strategic insights will be invaluable as we continue to develop and advance our therapeutic vaccine to address an unmet medical need of achieving remission in HIV."

"I am extremely happy to join Immgenuity's Board of Directors and contribute to the development of Immgenuity's therapeutic vaccine that has the potential to make a significant impact on patients' lives," said Senator Allen.

"Immgenuity's innovative approach to achieving a remission in HIV and its focus on addressing this unmet medical need aligns with my own values and passion for forward progress in healthcare."

Immgenuity's Board of Directors is composed of world-renowned experts in the fields of leadership, management and corporate governance. The Board provides guidance and strategic advice to Immgenuity's leadership team on operations and strategies of the company.

About Immgenuity

Immgenuity, Inc. is a biotechnology company dedicated to developing innovative immunotherapy solutions to improve the lives of patients suffering from HIV. The company's lead product candidate is IMTV014, a novel immunotherapy for HIV and NeuroAIDS, which has shown to be safe in preclinical studies. Immgenuity, Inc. is headquartered in Dover, Delaware and is led by a team of experienced biotech professionals with deep expertise in infectious diseases, immunology, virology, and drug development. For more information, visit

<https://immgenuity.com>

About IMTV014

Immgenuity's immunotherapy, IMTV014 is a genetically modified HIV virus which is unable to block immune signaling like the natural HIV does. By restoring immune signaling, IMTV014 plans to activate the immune system to create a strong, viable immune response against HIV and likely lead to clearing the virus even from the sanctuary areas where the virus persists despite aggressive anti-HIV drug treatment. IMTV014 will also address various neurological and cardiovascular comorbidities caused by the virus persistence in these anatomical sanctuary areas via prolonged and elevated secretion of inflammatory cytokines. IMTV014 also has application as "salvage therapy" in the multidrug resistant population.

Contact: Media Relations: media@immgenuity.com (302) 321-5844

Forward Looking Statements:

This press release contains "forward-looking statements" within the meaning of federal securities law, including statements concerning the company's outlook for 2023 and beyond; business strategies and their anticipated results; and similar statements concerning anticipated future events and expectations that are not historical facts. The forward-looking statements in this letter are subject to numerous risks and uncertainties, including the effects of economic conditions; supply and demand changes; competitive conditions in the industry; relationships with clients and distributors; the impact of government regulations; and the availability of capital to finance growth, which could cause actual results to differ materially from those expressed in or implied by the statements herein.